DOCSLIB.ORG

Pacs by Chemical Name (Pdf)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pacs by Chemical Name (Pdf) Table 2: Protective Action Criteria (PAC) Rev 26 based on applicable 60-minute AEGLs, ERPGs, or TEELs. The chemicals are listed in alphabetical order. September 2010 Table 2 is an alphabetical list of the chemical substances and their corresponding PAC values. For the most part, values are given in parts per million (ppm) for gases and volatile liquids and in milligrams per cubic meter (mg/m3) for solids, particulates (aerosols), and nonvolatile liquids. There is a column that indicates which TEEL or PAC values have changed since the last revision. The final column in this table contains technical comments and information provided by the PAC Development Team. The columns presented in Table 2 provide the following information: Heading Definition The ordered numbering of the chemicals as they appear in this No. alphabetical listing The name of the chemical substance submitted to the PAC Chemical Name development team CASRN The Chemical Abstract Service Registry Number1 for each chemical This is the threshold concentration below which most people will TEEL-0 experience no adverse health effects. This value is always referred to as a TEEL-0 because AEGL-0 and ERPG-0 values do not exist. PAC-1 Based on the applicable AEGL-1, ERPG-1, or TEEL-1 value PAC-2 Based on the applicable AEGL-2, ERPG-2, or TEEL-2 value PAC-3 Based on the applicable AEGL-3, ERPG-3, or TEEL-3 value Units The units for the PAC values (ppm or mg/m3) Values changed from Any PAC/TEEL values that have changed are indicated in red by PAC Rev. 25 name T-0, P-1, P-2, and/or P-3. TEEL-0 = T-0, PAC-1 = P-1, PAC-2 = P-2, PAC-3 = P-3 Technical comments are provided by the PAC Development Team. Comments Future efforts include reviewing, revising, and enhancing this information. Chemicals for which AEGLs are available have their chemical name, CASRN, and the AEGL values displayed in a bolded and larger font. Chemicals for which ERPGs are available, but not AEGLs, have their chemical name, CASRN, and the ERPG values displayed in a bolded font. Chemicals for which only TEELs are available, have their chemical name, CASRN, and values displayed using a regular font. 1 Information on the Chemical Abstract Service and CASRNs is provided at http://info.cas.org/. Introduction to PAC Table 2 – PAC Rev 26 – September 2010 Some values in Table 2 have the following text formatting: . Bold, green, and italicized font indicates the PAC value is between 10% and up to 50% of the LEL (10% LEL ≤ PAC < 50% LEL). Bold, underlined, pink and italicized font indicates the PAC value is between 50% and up to 100% of the LEL (50% LEL ≤ PAC < 100% LEL). Bold, double underlined, red and italicized font indicates the PAC value is at 100% or more of the LEL (PAC ≥ LEL). Additional information on PAC values, TEEL values, and links to other sources of information is provided on the Subcommittee for Consequence Assessment and Protective Action (SCAPA) webpage at: http://orise.orau.gov/emi/scapa/teels.htm. Introduction to PAC Table 2 – PAC Rev 26 – September 2010 September 2010 Table 2: Protective Action Criteria (PAC) Rev 26 PAC Rev 26 Based on applicable AEGLs, ERPGs, or TEELs (Chemicals listed in alphabetical order) PAC based on AEGLs, ERPGs, or TEELs Values changed from PAC Rev 25: No. Chemical Name CASRN Comments TEEL-0 = T-0, PAC-1 = P-1, TEEL-0 PAC-1 PAC-2 PAC-3 Units PAC-2 = P-2, PAC-3 = P-3 1 Acacia; (Gum arabic) 9000-01-5 200 500 500 500 mg/m3 2 Acenaphthene 83-32-9 0.4 1.25 7.5 250 mg/m3 3 Acenaphthylene 208-96-8 0.06 0.2 1.5 500 mg/m3 4 Acetaldehyde 75-07-0 25 45 270 840 ppm Interim AEGL-1, -2, -3 5 Acetamide 60-35-5 25 75 500 500 mg/m3 6 Acetanilide 103-84-4 0.4 1 7.5 50 mg/m3 7 Acetic acid 64-19-7 5 5 35 250 ppm ERPG-1, -2, -3 Acetic acid ethenyl ester, polymer TSCA listed, no toxicity or 8 with 1,1-bis(ethenyloxy) butane 27360-07-2 10 30 50 250 mg/m3 pchem data found. and ethenol 9 Acetic acid, 2-propenyl ester 591-87-7 0.5 1.5 10 50 ppm 10 Acetic acid, lithium salt 546-89-4 12.5 35 250 500 mg/m3 Acetic acid, manganese(2+) salt, 11 6156-78-1 4.46 13.4 22.3 500 mg/m3 T-0 Changed "N" to "Y" tetrahydrate Acetic acid, manganese(II) salt 12 638-38-0 3.15 9.45 15.7 500 mg/m3 T-0 Changed "N" to "Y" (2:1) 13 Acetic anhydride 108-24-7 0.5 0.5 15 100 ppm ERPG-1, -2, -3 Interim AEGL-1, -2, -3 14 Acetone 67-64-1 200 200 3200 5700 ppm See LEL formatting note 15 Acetone thiosemicarbazide 1752-30-3 20 60 100 100 mg/m3 Pchem data from ChemFinder 16 Acetone-d6 666-52-4 200 200 3,200 5,700 ppm See LEL formatting note. 17 Acetonitrile 75-05-8 13 13 320 670 ppm Interim AEGL-1, -2, -3 18 Acetonitrile-d3 2206-26-0 13 13 320 670 ppm ChemFinder MW and MF Chemicals with AEGLs: large, bolded font. ERPGs (but no AEGLs): bolded font. Bold green italics: 10% LEL ≤ PAC < 50% LEL; bold underlined pink italics: 50% LEL ≤ PAC < 100% LEL; bold double underlined red italcs: PAC ≥ LEL. 1 September 2010 Table 2: Protective Action Criteria (PAC) Rev 26 PAC Rev 26 Based on applicable AEGLs, ERPGs, or TEELs (Chemicals listed in alphabetical order) PAC based on AEGLs, ERPGs, or TEELs Values changed from PAC Rev 25: No. Chemical Name CASRN Comments TEEL-0 = T-0, PAC-1 = P-1, TEEL-0 PAC-1 PAC-2 PAC-3 Units PAC-2 = P-2, PAC-3 = P-3 19 Acetophenone 98-86-2 10 10 60 200 mg/m3 P-1, P-2, P-3 20 Acetoxytriphenylstannane 900-95-8 0.345 0.689 20 86.2 mg/m3 21 Acetyl bromide 506-96-7 0.2 0.6 4 20 ppm Acetyl carbinol; (Acetol (1); 1- 22 116-09-6 7.5 25 200 500 mg/m3 Hydroxy-2-propanone) 23 Acetyl chloride 75-36-5 0.0025 0.0075 0.05 125 ppm 24 Acetyl triethyl citrate 77-89-4 6 20 125 500 mg/m3 25 Acetylaminofluorene, 2- 53-96-3 2.5 7.5 50 350 mg/m3 T-0, P-1, P-2 Toxicity data updated. 26 Acetylaminofluorenone, 2- 3096-50-2 0.75 2.5 15 75 mg/m3 Toxicity data updated. 27 Acetylene 74-86-2 125 350 2,500 6,000 ppm See LEL formatting note. 28 Acrolein 107-02-8 0.03 0.030 0.10 1.4 ppm Interim AEGL-1, -2, -3 29 Acrylamide 79-06-1 0.03 15 60 60 mg/m3 T-1 Acrylamide, N,N'- No toxicity data found, PNOS 30 methylenebisacrylamide 25034-58-6 10 30 50 250 mg/m3 default used copolymer 31 Acrylic acid 79-10-7 1.5 1.5 46 180 ppm Interim AEGL-1, -2, -3 Acrylic acid polymers; (Acrylic 32 9003-01-4 10 30 200 500 mg/m3 polymer or resin) 33 Acrylonitrile 107-13-1 2 10 35 75 ppm ERPG-1, -2, -3 34 Acrylyl chloride; (Acryloyl chloride) 814-68-6 0.05 0.15 0.243 10 ppm Adamsite; (Phenarsazine 35 578-94-9 0.016 0.016 2.6 6.40 mg/m3 Interim AEGL-1, -2, -3 chloride) 36 Adipic acid 124-04-9 5 5 5 125 mg/m3 Chemicals with AEGLs: large, bolded font. ERPGs (but no AEGLs): bolded font. Bold green italics: 10% LEL ≤ PAC < 50% LEL; bold underlined pink italics: 50% LEL ≤ PAC < 100% LEL; bold double underlined red italcs: PAC ≥ LEL. 2 September 2010 Table 2: Protective Action Criteria (PAC) Rev 26 PAC Rev 26 Based on applicable AEGLs, ERPGs, or TEELs (Chemicals listed in alphabetical order) PAC based on AEGLs, ERPGs, or TEELs Values changed from PAC Rev 25: No. Chemical Name CASRN Comments TEEL-0 = T-0, PAC-1 = P-1, TEEL-0 PAC-1 PAC-2 PAC-3 Units PAC-2 = P-2, PAC-3 = P-3 Adipic acid, diethylene glycol, trimethylolpropane, phthalic No toxicity or pchem data found. 37 68609-57-4 10 30 50 250 mg/m3 anhydride, toluenediisocyanate Name changed. polymer, isocyanate terminated 38 Adiponitrile 111-69-3 2 3.85 3.85 150 ppm Aerosol, A-102; (Poly(oxy-1,2- ethanediyl), alpha-(3-carboxy-1- No pchem data found, assumed 39 39354-45-5 125 400 500 500 mg/m3 oxo-3-sulfopropyl)-omega- density = 1.00. (dodecyloxy)-, disodium salt) 40 Agar 9002-18-0 500 500 500 500 mg/m3 Agarose, type VII (low gelling 41 9012-36-6 10 30 50 250 mg/m3 No data found. temperature); (Sepharose) 42 Alamine 336 68814-95-9 20 60 500 500 mg/m3 No pchem data found. Used human serum Albumin 43 Albumin (bovine) 9048-46-8 150 500 500 500 mg/m3 toxicity data. TSCA listed, no toxicity or 44 Alcohol oxidase 9073-63-6 10 30 50 250 mg/m3 pchem data found. N.O.S. = Not Otherwise 45 Alcohols, C6-C12 (N.O.S.) 68603-15-6 10 30 50 250 mg/m3 Specified. Aldrin; (1,2,3,4,10,10-Hexachloro- 1,4,4a,5,8,8a-hexahydro-1,4- 46 309-00-2 0.05 1.5 10 25 mg/m3 T-0, P-1 PEL-TWA suppressed endo,exo-5,8- dimethanonaphthalene) Synonym, MW, MF, MP in 47 Aldrithiol-2; (2,2'-Dithiodipyridine) 2127-03-9 10 30 50 250 mg/m3 ChemFinder.
Load more

Recommended publications
  • Belize Pesticides Control Act Chapter 216 Revised Edition
    BELIZE PESTICIDES CONTROL ACT CHAPTER 216 REVISED EDITION 2000 SHOWING THE LAW AS AT 31ST DECEMBER, 2000 This is a revised edition of the law, prepared by the Law Revision Commissioner under the authority of the Law Revision Act, Chapter 3 of the Laws of Belize, Revised Edition 1980 - 1990. This edition contains a consolidation of the following laws- Page ARRANGEMENT OF SECTIONS 3 PESTICIDES CONTROL ACT 5 Amendments in force as at 31st December, 2000. BELIZE PESTICIDES CONTROL ACT CHAPTER 216 REVISED EDITION 2000 SHOWING THE LAW AS AT 31ST DECEMBER, 2000 This is a revised edition of the law, prepared by the Law Revision Commissioner under the authority of the Law Revision Act, Chapter 3 of the Laws of Belize, Revised Edition 1980 - 1990. This edition contains a consolidation of the following laws- Page ARRANGEMENT OF SECTIONS 3 PESTICIDES CONTROL ACT 5 Amendments in force as at 31st December, 2000. Pesticides Control [CAP. 216 3 CHAPTER 216 PESTICIDES CONTROL ARRANGEMENT OF SECTIONS 1. Short title. 2. Interpretation. 3. Establishment of Pesticides Control Board. 4. Functions of the Board. 5. Policy directions. 6. Registered pesticides. 7. Licensing of manufacturer or importer of pesticides. 8. Restricted pesticides, authorisation to sell restricted pesticides and regis- tration of premises. 9. Authorisation of applicators. 10. Duties of the Secretary. 11. Correction of registers. 12. Suspension and deletion of entry from registers. 13. Prohibited pesticides. 14. Packaging. THE SUBSTANTIVE LAWS OF BELIZE REVISED EDITION 2000 Printed by the Government Printer, No. 1 Power Lane, Belmopan, by the authority of []the Government of Belize. 4 CAP.
    [Show full text]
  • Laxatives for the Management of Constipation in People Receiving Palliative Care (Review)
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by UCL Discovery Laxatives for the management of constipation in people receiving palliative care (Review) Candy B, Jones L, Larkin PJ, Vickerstaff V, Tookman A, Stone P This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2015, Issue 5 http://www.thecochranelibrary.com Laxatives for the management of constipation in people receiving palliative care (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 4 METHODS ...................................... 4 RESULTS....................................... 7 Figure1. ..................................... 8 Figure2. ..................................... 9 Figure3. ..................................... 10 DISCUSSION ..................................... 13 AUTHORS’CONCLUSIONS . 14 ACKNOWLEDGEMENTS . 14 REFERENCES ..................................... 15 CHARACTERISTICSOFSTUDIES . 17 DATAANDANALYSES. 26 ADDITIONALTABLES. 26 APPENDICES ..................................... 28 WHAT’SNEW..................................... 35 HISTORY....................................... 35 CONTRIBUTIONSOFAUTHORS . 36 DECLARATIONSOFINTEREST . 36 SOURCESOFSUPPORT . 36 DIFFERENCES
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Managing Constipation in Adults
    Managing Constipation in Adults Opio id Induced Constipation ● Use an osmotic laxative (or docusate which also softens stools and a stimulant laxative (consider dantron in terminally ill patients). • Treat any underlying causes of condition (e.g. hypothyroidism, haemorrhoids or anal fissures) ● Naloxegol is recommended by NICE TA345 as an option when opioid induced constipation has not adequately responded to laxatives. • Consider Red Flags (See Box A ) An inadequate response is defined as opioid-induced of at least moderate severity in at least 1of the 4 stool symptoms domain (i.e. incomplete bowel movement, hard stool, straining or false alarm) Review medication –consider stopping any medication that may be causing constipation (see Box B ) whilst taking1 laxative class for at least 4 days during the prior 2 weeks. ● Avoid bulk -forming l axatives for treating opioid induced constipation Acute Constipation Chronic Constipation ● Check for faecal loading and manage appropriately Lifestyle advise -to increase fibre in diet (see Box C ), adequate fluid and exercise ● Set realistic expectations for the results of treatment of chronic constipation. Chronic Constipation: First Line treatment • Adjust the dose, choice, and combination of laxative according to symptoms, speed with which Bulk forming laxatives i.e. ispaghula. relief is required, response to treatment, and individual preference. • Ensure adequate fluid intake (caution- frail elderly patients) • The dose of laxative should be gradually titrated upwards (or downwards) to produce one or two • May take several days to act- so not suitable if rapid relief required. soft, formed stools per day. • Not appropriate for opiod induced constipation. • If at least two laxatives (from different classes) have been tried at the highest tolerated recommended doses for at least 6 months, consider the use of prucalopride in women only and lubiprostone for adults with chronic idiopathic constipation.
    [Show full text]
  • COMPASS Therapeutic Notes on the Management of Chronic Constipation in Primary Care
    COMPASS Therapeutic Notes on the Management of Chronic Constipation in Primary Care In this issue: Glossary Page Chronic Constipation lasting longer than 3 months Introduction and background 1 constipation Drugs used in the management of Functional Chronic constipation without a known cause. Also known as primary 3 chronic constipation constipation constipation or idiopathic constipation Bulk-forming laxatives 4 Gastrocolic The occurrence of peristalsis following the entrance of food into the Osmotic laxatives 5 response empty stomach Stimulant laxatives 6 IBS Irritable Bowel Syndrome IBS-C Irritable Bowel Syndrome with Constipation Faecal softeners 7 Melanosis Dark brownish black pigmentation of the mucous membrane of the colon Peripheral opioid-receptor 7 coli due to the deposition of pigment in macrophages antagonists Myenteric Part of the enteric nervous system with an important role in regulating 5HT4 – receptor agonists 7 plexus gut motility Managing constipation in 8 NNT Number Needed to Treat pregnancy and breastfeeding OTC Over The Counter RCT Randomised Controlled Trial Secondary Constipation caused by a drug or medical condition. Secondary constipation constipation is also known as organic constipation SmPC Summary of Product Characteristics A twisting or looping of the bowel resulting in obstruction; can be life- Volvulus threatening Successful completion of the assessment questions at the end of this issue will provide you with 2 hours towards your CPD/CME requirements. Further copies of this and any other edition in the
    [Show full text]
  • 1: Gastro-Intestinal System
    1 1: GASTRO-INTESTINAL SYSTEM Antacids .......................................................... 1 Stimulant laxatives ...................................46 Compound alginate products .................. 3 Docuate sodium .......................................49 Simeticone ................................................... 4 Lactulose ....................................................50 Antimuscarinics .......................................... 5 Macrogols (polyethylene glycols) ..........51 Glycopyrronium .......................................13 Magnesium salts ........................................53 Hyoscine butylbromide ...........................16 Rectal products for constipation ..........55 Hyoscine hydrobromide .........................19 Products for haemorrhoids .................56 Propantheline ............................................21 Pancreatin ...................................................58 Orphenadrine ...........................................23 Prokinetics ..................................................24 Quick Clinical Guides: H2-receptor antagonists .......................27 Death rattle (noisy rattling breathing) 12 Proton pump inhibitors ........................30 Opioid-induced constipation .................42 Loperamide ................................................35 Bowel management in paraplegia Laxatives ......................................................38 and tetraplegia .....................................44 Ispaghula (Psyllium husk) ........................45 ANTACIDS Indications:
    [Show full text]
  • The List of Extremely Hazardous Substances)
    APPENDIX A (THE LIST OF EXTREMELY HAZARDOUS SUBSTANCES) THRESHOLD REPORTABLE INVENTORY RELEASE QUANTITY QUANTITY CAS NUMBER CHEMICAL NAME (POUNDS) (POUNDS) 75-86-5 ACETONE CYANOHYDRIN 500 10 1752-30-3 ACETONE THIOSEMICARBAZIDE 500/500 1,000 107-02-8 ACROLEIN 500 1 79-06-1 ACRYLAMIDE 500/500 5,000 107-13-1 ACRYLONITRILE 500 100 814-68-6 ACRYLYL CHLORIDE 100 100 111-69-3 ADIPONITRILE 500 1,000 116-06-3 ALDICARB 100/500 1 309-00-2 ALDRIN 500/500 1 107-18-6 ALLYL ALCOHOL 500 100 107-11-9 ALLYLAMINE 500 500 20859-73-8 ALUMINUM PHOSPHIDE 500 100 54-62-6 AMINOPTERIN 500/500 500 78-53-5 AMITON 500 500 3734-97-2 AMITON OXALATE 100/500 100 7664-41-7 AMMONIA 500 100 300-62-9 AMPHETAMINE 500 1,000 62-53-3 ANILINE 500 5,000 88-05-1 ANILINE,2,4,6-TRIMETHYL- 500 500 7783-70-2 ANTIMONY PENTAFLUORIDE 500 500 1397-94-0 ANTIMYCIN A 500/500 1,000 86-88-4 ANTU 500/500 100 1303-28-2 ARSENIC PENTOXIDE 100/500 1 THRESHOLD REPORTABLE INVENTORY RELEASE QUANTITY QUANTITY CAS NUMBER CHEMICAL NAME (POUNDS) (POUNDS) 1327-53-3 ARSENOUS OXIDE 100/500 1 7784-34-1 ARSENOUS TRICHLORIDE 500 1 7784-42-1 ARSINE 100 100 2642-71-9 AZINPHOS-ETHYL 100/500 100 86-50-0 AZINPHOS-METHYL 10/500 1 98-87-3 BENZAL CHLORIDE 500 5,000 98-16-8 BENZENAMINE, 3-(TRIFLUOROMETHYL)- 500 500 100-14-1 BENZENE, 1-(CHLOROMETHYL)-4-NITRO- 500/500 500 98-05-5 BENZENEARSONIC ACID 10/500 10 3615-21-2 BENZIMIDAZOLE, 4,5-DICHLORO-2-(TRI- 500/500 500 FLUOROMETHYL)- 98-07-7 BENZOTRICHLORIDE 100 10 100-44-7 BENZYL CHLORIDE 500 100 140-29-4 BENZYL CYANIDE 500 500 15271-41-7 BICYCLO[2.2.1]HEPTANE-2-CARBONITRILE,5-
    [Show full text]
  • National Institute for Clinical Excellence
    Appendix C NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal (STA) Lubiprostone for treating opioid-induced constipation in people with chronic, non-cancer pain Matrix of consultees and commentators Consultees Commentators (no right to submit or appeal) Manufacturers/sponsors General Sucampo Pharma Europe Allied Health Professionals Federation (lubiprostone) Board of Community Health Councils in Wales Patient/carer groups British National Formulary Action on Pain Care Quality Commission Afiya Trust Commissioning Support Appraisals Black Health Agency Service Bladder and Bowel Foundation Department of Health, Social Services Equalities National Council and Public Safety for Northern Ireland Muslim Council of Britain Healthcare Improvement Scotland Muslim Health Network Medicines and Healthcare products Pain Concern Regulatory Agency Pain Relief Foundation National Association of Primary Care Pain UK National Pharmacy Association PromoCon NHS Alliance South Asian Health Foundation NHS Commercial Medicines Unit Specialised Healthcare Alliance NHS Confederation IBS Network Public Health Wales NHS Trust Scottish Medicines Consortium Professional groups Association of Coloproctology of Great Comparator manufacturers Britain and Ireland Abbott Laboratories UK (lactulose) Association for Continence Advice Actavis UK (glycerol suppositories), Association for Palliative Medicine Amdipharm (methylcellulose) British Geriatrics Society Bell Sons & Co (Druggists) Limited British Pain
    [Show full text]
  • A Four-Country Comparison of Healthcare Systems, Implementation
    Neurogastroenterology & Motility Neurogastroenterol Motil (2014) 26, 1368–1385 doi: 10.1111/nmo.12402 REVIEW ARTICLE A four-country comparison of healthcare systems, implementation of diagnostic criteria, and treatment availability for functional gastrointestinal disorders A report of the Rome Foundation Working Team on cross-cultural, multinational research M. SCHMULSON,* E. CORAZZIARI,† U. C. GHOSHAL,‡ S.-J. MYUNG,§ C. D. GERSON,¶ E. M. M. QUIGLEY,** K.-A. GWEE†† & A. D. SPERBER‡‡ *Laboratorio de Hıgado, Pancreas y Motilidad (HIPAM)-Department of Experimental Medicine, Faculty of Medicine-Universidad Nacional Autonoma de Mexico (UNAM). Hospital General de Mexico, Mexico City, Mexico †Gastroenterologia A, Department of Internal Medicine and Medical Specialties, University La Sapienza, Rome, Italy ‡Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Science, Lucknow, India §Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea ¶Division of Gastroenterology, Mount Sinai School of Medicine, New York, NY, USA **Division of Gastroenterology and Hepatology, Houston Methodist Hospital and Weill Cornell Medical College, Houston, TX, USA ††Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore ‡‡Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel Key Messages • This report identified seven key issues related to healthcare provision that may impact how patients with FGIDs are investigated, diagnosed and managed. • Variations in healthcare provision around the world in patients with FGIDs have not been reviewed. • We compared four countries that are geographically and culturally diverse, and exhibit differences in the healthcare coverage provided to their population: Italy, South Korea, India and Mexico. • Since there is a paucity of publications relating to the issues covered in this report, some of the findings are based on the authors’ personal perspectives, press reports and other published sources.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • High Hazard Chemical Policy
    Environmental Health & Safety Policy Manual Issue Date: 2/23/2011 Policy # EHS-200.09 High Hazard Chemical Policy 1.0 PURPOSE: To minimize hazardous exposures to high hazard chemicals which include select carcinogens, reproductive/developmental toxins, chemicals that have a high degree of toxicity. 2.0 SCOPE: The procedures provide guidance to all LSUHSC personnel who work with high hazard chemicals. 3.0 REPONSIBILITIES: 3.1 Environmental Health and Safety (EH&S) shall: • Provide technical assistance with the proper handling and safe disposal of high hazard chemicals. • Maintain a list of high hazard chemicals used at LSUHSC, see Appendix A. • Conduct exposure assessments and evaluate exposure control measures as necessary. Maintain employee exposure records. • Provide emergency response for chemical spills. 3.2 Principle Investigator (PI) /Supervisor shall: • Develop and implement a laboratory specific standard operation plan for high hazard chemical use per OSHA 29CFR 1910.1450 (e)(3)(i); Occupational Exposure to Hazardous Chemicals in Laboratories. • Notify EH&S of the addition of a high hazard chemical not previously used in the laboratory. • Ensure personnel are trained on specific chemical hazards present in the lab. • Maintain Material Safety Data Sheets (MSDS) for all chemicals, either on the computer hard drive or in hard copy. • Coordinate the provision of medical examinations, exposure monitoring and recordkeeping as required. 3.3 Employees: • Complete all necessary training before performing any work. • Observe all safety
    [Show full text]
  • List of Extremely Hazardous Substances
    Emergency Planning and Community Right-to-Know Facility Reporting Compliance Manual List of Extremely Hazardous Substances Threshold Threshold Quantity (TQ) Reportable Planning (pounds) Quantity Quantity (Industry Use (pounds) (pounds) CAS # Chemical Name Only) (Spill/Release) (LEPC Use Only) 75-86-5 Acetone Cyanohydrin 500 10 1,000 1752-30-3 Acetone Thiosemicarbazide 500/500 1,000 1,000/10,000 107-02-8 Acrolein 500 1 500 79-06-1 Acrylamide 500/500 5,000 1,000/10,000 107-13-1 Acrylonitrile 500 100 10,000 814-68-6 Acrylyl Chloride 100 100 100 111-69-3 Adiponitrile 500 1,000 1,000 116-06-3 Aldicarb 100/500 1 100/10,000 309-00-2 Aldrin 500/500 1 500/10,000 107-18-6 Allyl Alcohol 500 100 1,000 107-11-9 Allylamine 500 500 500 20859-73-8 Aluminum Phosphide 500 100 500 54-62-6 Aminopterin 500/500 500 500/10,000 78-53-5 Amiton 500 500 500 3734-97-2 Amiton Oxalate 100/500 100 100/10,000 7664-41-7 Ammonia 500 100 500 300-62-9 Amphetamine 500 1,000 1,000 62-53-3 Aniline 500 5,000 1,000 88-05-1 Aniline, 2,4,6-trimethyl- 500 500 500 7783-70-2 Antimony pentafluoride 500 500 500 1397-94-0 Antimycin A 500/500 1,000 1,000/10,000 86-88-4 ANTU 500/500 100 500/10,000 1303-28-2 Arsenic pentoxide 100/500 1 100/10,000 1327-53-3 Arsenous oxide 100/500 1 100/10,000 7784-34-1 Arsenous trichloride 500 1 500 7784-42-1 Arsine 100 100 100 2642-71-9 Azinphos-Ethyl 100/500 100 100/10,000 86-50-0 Azinphos-Methyl 10/500 1 10/10,000 98-87-3 Benzal Chloride 500 5,000 500 98-16-8 Benzenamine, 3-(trifluoromethyl)- 500 500 500 100-14-1 Benzene, 1-(chloromethyl)-4-nitro- 500/500
    [Show full text]